Table 2.

Adenosine receptor drugs in cardiovascular and metabolic diseases.

Receptors	Functions		Diseases	Drugs
				Selective Full Agonist	Antagonist/Partial Agonist
A1AR	Inotropic and adrenergic control	Negative	Heart failure	CPA [106]	BG9928 [107] Rolofylline [108] Capadenoson [122] Neladenoson [124]
	Dromotropic and chronotropic control	Negative	Arrhythmia	Tecadenoson (DC)[128] Selodenoson [129] PJ-875 [129]	CVT-2759 [130]
	Vascular control	Constriction	Hypertension
	Ischemia	Protection	Angina		Capadenoson [121]
	Adaptation	Hypertrophy		CPA [106]
		Angiogenesis
			Diabetes mellitus and hyperlipidemia	GR79236 and ARA [165] SDZ WAG994 and RPR749 [123] Tecadenoson [168]	GS-9667/CVT-3619 [167] BW-1433 [168]
			Glaucoma	Trabodenoson (DC) [123]
			Glomerulonephritis	Metrifudil 2 (DC) [123]
A2AAR	Inotropic and adrenergic control	Positive	Heart failure	LASSBio-294 [184]
	Vascular control	Dilatation	Imaging	Regadenoson, binodenoson, evodenoson, sonedenoson, and apadenoson [123,185]
	Anti-inflammation		Platelet aggregation	PSB-15826, PSB-12404, and PSB-16301 [186]
			Cholesterol homeostasis	ATL313 [187]
	Ischemia	Protection	Angina	CGS 21680C [180] ATL-193/ATL-146e [181]
	Adaptation	Hypertrophy
		Angiogenesis
A2BAR	Vascular control	Dilatation
	Anti-inflammation		Atherosclerosis and hyperlipidemia	BAY 60-6853 [189]
	Ischemia	Protection	Angina	BAY 60-6583 [190]
	Adaptation	Hypertrophy
		Angiogenesis			GS-6201 [191]
			Diabetes mellitus and hyperlipidemia		NECA [192] ATL-801 [193] MRS-1754 [194]
A3AR	Vascular control	Constriction
	Anti-inflammation		Diabetic kidney diseases		LJ-2698 [195]
			Atherosclerosis and hyperlipidemia		LJ-1888 [196]
	Ischemia	Protection	Angina	IB-MECA [197] CI-IB-MECA [198] CP-532,903 [199]
	Adaptation		Hypertrophy
			Angiogenesis